New Data Shows Ranexa(R) Increases Glucose Stimulated Insulin Secretion
The Company believes that the increase in GSIS seen with ranolazine may contribute to the statistically significant reductions in hemoglobin A1c (HbA1c) levels observed with Ranexa in cardiovascular patients with diabetes from the phase 3 CARISA (n=189 with angina and diabetes) and MERLIN-TIMI 36 (n=2,220 with acute coronary syndromes and diabetes) clinical trials. In CARISA, Ranexa reduced HbA1c levels by an average of up to 0.7 percentage points. In MERLIN-TIMI 36, Ranexa lowered HbA1c versus placebo by an average of 0.43 percentage points at four months in patients with a mean baseline HbA1c level of 7.5%.
The preclinical results presented showed that ranolazine increased GSIS in a dose-dependent manner in isolated islets. Acute administration of ranolazine to animals also significantly increased GSIS in the presence of a glucose load (p
Noi date Afiºeazã Ranexa (R) Creºterea Glucoza stimulat secreþia de insulinã - New Data Shows Ranexa(R) Increases Glucose Stimulated Insulin Secretion - articole medicale engleza - startsanatate